Single cell sequencing opens new avenues for eradicating leukemia at its source

Single cell sequencing opens new avenues for eradicating leukemia at its source
Image of stem cells (blue) in bone marrow together with a sinusoidal blood vessel (red) and an arteriolar blood vessel. Single cell sequencing is a promising method because it can help discriminate between healthy stem cells and potentially cancerous ones that cannot be identified via imaging. Credit: Jude Al-Sabah/DKFZ

A new method, described in a study published today in the journal Nature Communications, has the potential to boost international research efforts to find drugs that eradicate cancer at its source.

Most consists of rapidly dividing with a limited capacity for self-renewal, meaning that the bulk of cells stop reproducing after a certain number of divisions. However, cancer stem cells can replicate indefinitely, fueling long-term cancer growth and driving relapse.

Cancer stem cells that elude conventional treatments like chemotherapy are one reason patients initially enter remission but relapse soon after. In acute myeloid leukemia, a form of blood cancer, the high probability of relapse means fewer than 15% of elderly patients live longer than five years.

However, cancer stem cells are difficult to isolate and study because of their low abundance and similarity to other stem cells, hampering international research efforts in developing precision treatments that target while sparing healthy ones.

Researchers from the Centre for Genomic Regulation (CRG) and the European Molecular Biology Laboratory (EMBL) have overcome this problem by creating MutaSeq, a method that can be used to distinguish cancer stem cells, mature cancer cells and otherwise healthy based on their genetics and gene expression.

"RNA provides vital information for human health. For example, PCR tests for coronavirus detect its RNA to diagnose COVID-19. Subsequent sequencing can determine the virus variant," explains Lars Velten, Group Leader at the CRG and author of the paper. "MutaSeq works like a PCR test for coronavirus, but at a much more complex level and with a single cell as starting material."

To determine if a single cell is a stem cell, the researchers used MutaSeq to measure thousands of RNAs at the same time. To then find out if the cell is cancerous or healthy, the researchers carried out additional sequencing and looked for mutations. The resulting data helped researchers track if stems cells are cancerous or healthy and helped determine what makes the different.

"There are a huge number of small molecule drugs out there with demonstrated clinical safety, but deciding which cancers and more specifically which patients these drugs are well suited for is a daunting task," says Lars Steinmetz, Professor at Stanford University, Group Leader at EMBL Heidelberg and author of the paper. "Our method can identify drug targets that might not have been tested in the right context. These tests will need to be carried out in controlled clinical studies, but knowing what to try is an important first step."

The method is based on sequencing, an increasingly common technique that helps researchers gather and interpret genome-wide information from thousands of individual cells. Single cell sequencing provides a highly detailed molecular profile of complex tissues and cancers, opening new avenues for research.

Explaining their next steps, Lars Velten says: "We have now brought together clinical researchers from Germany and Spain to apply this method in much larger clinical studies. We are also making the method much more streamlined. Our vision is to identify stem cell specific drug targets in a personalized manner, making it ultimately as easy for patients and doctors to look for these treatments as it is testing for coronavirus."


Explore further

Targeting stem cells: The path to curing poor-prognosis leukaemia

More information: Lars Velten et al. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics, Nature Communications (2021). DOI: 10.1038/s41467-021-21650-1
Journal information: Nature Communications

Provided by Center for Genomic Regulation
Citation: Single cell sequencing opens new avenues for eradicating leukemia at its source (2021, March 1) retrieved 13 April 2021 from https://medicalxpress.com/news/2021-03-cell-sequencing-avenues-eradicating-leukemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
74 shares

Feedback to editors

User comments